July 24, 2026

CareDx, Inc. (CDNA) Stock Analysis: A Deep Dive into Its Future Growth Potential

CareDx, Inc. (NASDAQ: CDNA), a key player in the healthcare sector specializing in diagnostics and research, is attracting attention with its innovative solutions aimed at improving..

Syndax Pharmaceuticals, Inc. (SNDX) Investor Outlook: A Promising 83.88% Upside Potential

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX), a dynamic player in the biotechnology sector, presents a compelling case for investors seeking to capitalize on the promising growth in..

STAAR Surgical Company (STAA) Stock Analysis: Navigating Potential Upside Amidst Mixed Valuation Metrics

STAAR Surgical Company (NASDAQ: STAA), a prominent player in the healthcare sector, specializes in designing and manufacturing phakic implantable lenses for eye disorders. With a market..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: A Potential 533.66% Upside in the Biotech Sector

In the ever-evolving landscape of biotechnology, LENZ Therapeutics, Inc. (NASDAQ: LENZ) emerges as a compelling investment opportunity with a potential upside of 533.66%. This California-based company,..

Oculis Holding AG (OCS) Stock Analysis: Biotech’s Hidden Gem with a 224% Upside Potential

Oculis Holding AG (OCS), a Swiss-based clinical-stage biopharmaceutical company, is capturing investor attention with its promising drug pipeline and a staggering 224.44% potential upside. Operating within..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Exploring the 13.46% Upside Potential in Biotech

Bicara Therapeutics Inc. (NASDAQ: BCAX) stands out in the biotechnology sector, presenting a promising opportunity for investors keen on the healthcare industry. With a market capitalization..

Phibro Animal Health Corporation (PAHC) Stock Analysis: A 33.96% Potential Upside Beckons Investors

Phibro Animal Health Corporation (NASDAQ: PAHC), a key player in the healthcare sector specializing in drug manufacturing for both specialty and generic markets, is capturing investor..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 210.59% Potential Upside in Biotechnology

Gyre Therapeutics, Inc. (NASDAQ: GYRE) has been capturing the attention of investors with its promising pipeline in the biotechnology sector. Headquartered in San Diego, California, Gyre..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Exploring a Potential 50.60% Upside in the Pain Management Arena

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) stands out in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. With a market capitalization of $1.15..

Cronos Group Inc. (CRON) Stock Analysis: Examining a Promising 40.10% Revenue Growth Despite Market Challenges

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry, presents a compelling case for..

CorMedix Inc. (CRMD) Stock Analysis: A Biotech with a Promising 86% Potential Upside

CorMedix Inc. (NASDAQ: CRMD), a burgeoning player in the biotechnology sector, is capturing investor attention with its notable potential upside of 86.34%. This Parsippany, New Jersey-based..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: Exploring a Potential 23.89% Upside in Cutting-Edge Cancer Therapies

Arcus Biosciences, Inc. (NASDAQ: RCUS), a prominent name in the biotechnology sector, is capturing attention with its ambitious pipeline focused on innovative cancer therapies. With a..

Ardelyx, Inc. (ARDX) Stock Analysis: Exploring a 217% Potential Upside with Robust Buy Ratings

For investors eyeing the biotechnology sector, Ardelyx, Inc. (NASDAQ: ARDX) presents a compelling opportunity with its notable potential upside. With a market capitalization of $1.27 billion,..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Gem with a 26% Potential Upside

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is capturing the attention of investors with its promising biopharmaceutical innovations and a notable potential upside of 26.66%. As a clinical-stage..

Nutex Health Inc. (NUTX) Stock Analysis: Exploring a 60% Potential Upside in Healthcare Innovation

Nutex Health Inc. (NUTX), a notable player in the healthcare sector, operates a diverse business model encompassing hospitals, population health management, and real estate. With its..

Pension buy-out decisions put insurer service under greater scrutiny

Pension buy-outs are increasing the focus on insurer service quality, regulatory protection and long-term governance...

Arbuthnot Latham targets growing US expat wealth market

Arbuthnot Latham has launched a direct-investment service for US-connected clients managing wealth in the UK...

RM plc CFO Simon Goodwin discusses Assessment growth, RM Ava and full-year outlook

RM plc Chief Financial Officer Simon Goodwin discusses the drivers behind Assessment’s strong growth, progress on the RM Ava platform, further cost-saving opportunities and the Group’s..

James Cropper delivers strategy progress as profitability improves (LON:CRPR)

James Cropper CEO David Stirling and CFO Andrew Goody discuss improved profitability, debt reduction, growth in Advanced Materials and the recovery of Paper & Packaging...

Professor Sir Chris Evans outlines EDX Medical’s new workplace health screening service

EDX Medical’s Chief Scientific Officer discusses the service’s on-site testing model, competitive advantages, employer demand and potential to generate more than £2 million this financial year...
Search

Funds

July 24, 2026

Pension buy-out decisions put insurer service under greater scrutiny

Pension buy-outs are increasing the focus on insurer service quality, regulatory protection and long-term governance...

Arbuthnot Latham targets growing US expat wealth market

Arbuthnot Latham has launched a direct-investment service for US-connected clients managing wealth in the UK...

RM plc CFO Simon Goodwin discusses Assessment growth, RM Ava and full-year outlook

RM plc Chief Financial Officer Simon Goodwin discusses the drivers behind Assessment’s strong growth, progress on the RM Ava platform, further cost-saving opportunities and the Group’s expectations for the full year...

James Cropper delivers strategy progress as profitability improves (LON:CRPR)

James Cropper CEO David Stirling and CFO Andrew Goody discuss improved profitability, debt reduction, growth in Advanced Materials and the recovery of Paper & Packaging...

Professor Sir Chris Evans outlines EDX Medical’s new workplace health screening service

EDX Medical’s Chief Scientific Officer discusses the service’s on-site testing model, competitive advantages, employer demand and potential to generate more than £2 million this financial year...
Search

Funds

July 24, 2026

FTSE 100

Funds